SUSPECT ADVERSE REACTION REPORT

DO-Tolmar-TLM-2025-01108

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH			2a. AGE	3. SEX	4-6 REACTION ONSET		
		Day	Month	Year	Years		Day	Month	Year
AMS	DOMINICAN Cont..	05	Feb	1949	76	Female		Apr	2025

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data)

1) Cardiorespiratory arrest (Cardio-respiratory arrest (10007617), Cardio-respiratory arrest (10007617)) (18/Apr/2025 -) - Fatal
2) urinary tract infection (Urinary tract infection (10046571), Urinary tract infection (10046571)) Unknown
3) stroke cerebrovascular accident (Cerebrovascular accident (10008190), Cerebrovascular accident (10008190)) (08/Apr/2025 -) - Unknown
4) lung metastases (Lung metastases (10025111), Metastases to lung (10027458)) (/Apr/2025 -) - Unknown

Cont..

8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION

- [x] PATIENT DIED
- [ ] LIFE THREATENING
- [x] INVOLVED OR PROLONGED INPATIENT HOSPITALIZATION
- [ ] RESULTS IN PERSISTENCE OR SIGNIFICANT DISABILITY/INCAPACITY
- [ ] CONGENITAL ANOMALY
- [x] OTHER MEDICALLY IMPORTANT CONDITION

II. SUSPECT DRUG(S)INFORMATION

14. SUSPECT DRUG(S)(include generic name)

1) Eligard® (Leuprolide acetate, Leuprolide acetate) (Suspect) (Injection)(Unknown)

Cont..

15. DAILY DOSE(S)

1) (45 milligram(s), 1 in 6 Month)

Cont..

16. ROUTE(S) OF ADMINISTRATION

1) Subcutaneous

Cont..

17. INDICATION(S) FOR USE

1) Prostate cancer [10060862 - Prostate cancer]

Cont..

18. THERAPY DATE(S) (from/to)

1) (28/Oct/2024 -)

19. THERAPY DURATION

20. DID EVENT ABATE AFTER STOPPING DRUG? ☐ YES ☐ NO ☑ NA

21. DID EVENT REAPPEAR AFTER REINTRODUCTION ☐ YES ☐ NO ☑ NA

(NA : Not Applicable)

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)

No concomitants used/reported

23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)

1) PROSTATE CANCER (10060862, Prostate cancer) (Continuing: Yes)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER

Name : Tolmar, Inc
701 Centre Avenue
Fort Collins, CO, 80526, UNITED STATES OF AMERICA
debbie.maierhofer@tolmar.comand+1-4129158447

Study Information
Study Name: NA
EudraCT Number:
Protocol No.: NA
Center No.:
Subject Id :

24.REPORT NULLIFIED ☐ YES ☐ NO

24b. MFR CONTROL NO.

DO-Tolmar-TLM-2025-01108

24c. DATE RECEIVED BY MANUFACTURER

30/Apr/2025

24d. REPORT SOURCE ☑ STUDY ☐ LITERATURE ☐ HEALTH PROFESSIONAL

DATE OF THIS REPORT

03/May/2025

25a. REPORT TYPE ☑ INITIAL ☐ FOLLOWUP

= Continuation attached sheet(s)..

Continuation Sheet for CIOMS report

1a. COUNTRY

DOMINICAN REPUBLIC

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) (Continuation...)

Event Description :

This study report from Dominican Republic was received by Adium (reference number: DO-ADIUM-DO-0028-20250430) via Patient Support Program on 30-Apr-2025 from a consumer (patient's daughter) (non-healthcare professional) regarding an elderly 76-year-old male patient who experienced serious events of ‘cardiorespiratory arrest' (cardio-respiratory arrest) (death and medically significant), ‘stroke cerebrovascular accident' (cerebrovascular accident) (hospitalisation and medically significant), ‘lung metastases ‘ (metastases to lung) (medically significant) and ‘urinary tract infection' (urinary tract infection) (hospitalization) during Eligard (Leuprolide acetate) 45 milligram and 22.5 milligram therapy for prostate cancer. The needle component of the constituent device was not identified in the report. The report was sent to Tolmar on 30-Apr-2025.

The patient's medical history was unknown and current condition included prostate cancer.

Concomitant medications were unknown.

On 24-Jul-2023, the patient began receiving Eligard 22.5 mg, every 3 months via subcutaneous route for prostate cancer (Lot numbers and Expiration dates were not provided).

On an unknown date, the patient was hospitalized for a week for a urinary tract infection, which lasted four days.

On 28-Oct-2024, the patient received a dosage change to Eligard 45 mg, every 6 months via subcutaneous route for prostate cancer (Lot numbers and Expiration dates were not provided). The reason for dosage change was unknown.

On 08-Apr-2025, the patient was hospitalized for a stroke cerebrovascular accident that lasted approximately 10 days.

On unknown date in Apr-2025 (Between 08-Apr-2025 to 10-Apr-2025) the patient underwent CT and X-ray examinations and was diagnosed with lung metastasis.

On 18-Apr-2025, the patient died due to cardiorespiratory arrest while hospitalized at the clinic, and for this reason, he did not receive the dose of Eligard that was due on 29-Apr-2025. The patient was 76-year-old at the time of death. It was unknown if an autopsy was performed. No further details were available.

Further corrective treatment was not reported.

Relevant test results included:
On Unknown date-Apr-2025: CT scan and X-ray: lung metastasis (Ref. range: Not provided).

Action taken with Eligard (22.5 and 45 mg) in response to the event was not applicable. De-challenge and re-challenge were not applicable.

The outcome of cardiorespiratory arrest was fatal, and cerebrovascular accident, lung metastases, urinary tract infection was unknown.

The reporter assessed the seriousness of cardiorespiratory arrest (death), cerebrovascular accident and urinary tract infection (hospitalization) as serious. The reporter did not assess seriousness for event lung metastases.

The reporter did not provide the causality of cardiorespiratory arrest, cerebrovascular accident, lung metastases, urinary tract infection in relationship to Eligard (22.5 and 45 mg) and Eligard unspecified device.

No further queries were raised.

Listedness:

Cardio-respiratory arrest>Eligard>Unlisted as per CCDS>07-Nov-2024
Cardio-respiratory arrest>Eligard>Unlisted as per USPI>Feb-2025
Cardio-respiratory arrest>Eligard unspecified device>Unlisted as per USPI>Feb-2025
Cardio-respiratory arrest>Eligard>Unlisted as per Canadian monograph>02-Apr-2025

Urinary tract infection>Eligard>listed as per CCDS>07-Nov-2024
Urinary tract infection>Eligard>Unlisted as per USPI>Feb-2025
Urinary tract infection>Eligard unspecified device>Unlisted as per USPI>Feb-2025
Urinary tract infection>Eligard>Unlisted as per Canadian monograph>02-Apr-2025

Cerebrovascular accident>Eligard>listed as per CCDS>07-Nov-2024
Cerebrovascular accident>Eligard>listed as per USPI>Feb-2025

Continuation Sheet for CIOMS report

Cerebrovascular accident>Eligard unspecified device>listed as per USPI>Feb-2025
Cerebrovascular accident>Eligard>listed as per Canadian monograph>O2-Apr-2025

Metastases to lung>Eligard>listed as per CCDS>07-Nov-2024
Metastases to lung>Eligard>listed as per USPI>Feb-2025
Metastases to lung>Eligard unspecified device>listed as per USPI>Feb-2025
Metastases to lung>Eligard>listed as per Canadian monograph>O2-Apr-2025

Company Remarks (Sender's Comments) :

Evaluator comment (Tolmar): This is regarding an elderly 76-year-old male patient who died due to cardio-respiratory arrest (cardiorespiratory arrest) and experienced urinary tract infection (urinary tract infection), cerebrovascular accident (stroke cerebrovascular accident) and metastases to lung (lung metastases) during Eligard (leuprolide acetate) 45 mg and 22.5 mg therapy for prostate cancer. Tolmar assessed the event cardio-respiratory arrest as serious as it resulted in fatal outcome and is an IME event. Event urinary tract infection was assessed as serious as patient was hospitalised in response to the event. Event cerebrovascular accident was assessed as serious as it is an IME event and patient was hospitalised in response to event. Event lung metastases assessed as serious medically significant as it is an IME event. All the reported events were assessed as not related to Eligard 22.5 mg and 45 mg (drug and device) as the reported events can be confounded by underlying prostate cancer, associated with hypercoagulable state (increased thromboembolic risk) and advanced age of the patient.

Additional Information (Continuation...)

Lab Result :

Test Name	Test Date	Test Result	Normal Value
CT SCAN	/Apr/2025		
X-RAY	/Apr/2025		

Test Result (Code) / Result Unstructured Data (free text) :

1) Test Name: CT SCAN
Result Unstructured Data (free text) : Lung metastasis
Test Date: /Apr/2025
2) Test Name: X-RAY
Result Unstructured Data (free text) : Lung metastasis
Test Date: /Apr/2025

14.SUSPECT DRUG(S) (Continuation...)

Product-Reaction Level

1) Drug : Eligard® (Leuprolide acetate)
Active Substance : 1) Leuprolide acetate
Drug Characterization : Suspect
Form of Admin : 1) Injection
Lot Number : 1) Unknown
Daily Dose : (45 milligram(s), 1 in 6 Month)
Route of Admin : 1) Subcutaneous
Indications : 1) Prostate cancer [10060862 - Prostate cancer]
Therapy Dates : 1) From : 28/Oct/2024 To :Not applicable
Action(s) Taken With Drug : Not applicable

Causality

1) Cardiorespiratory arrest (Cardio-respiratory arrest - 10007617, Cardio-respiratory arrest - 10007617)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable
2) urinary tract infection (Urinary tract infection - 10046571, Urinary tract infection - 10046571)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable
3) stroke cerebrovascular accident (Cerebrovascular accident - 10008190, Cerebrovascular accident - 10008190)

Continuation Sheet for CIOMS report

Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

4) lung metastases (Lung metastases - 10025111, Metastases to lung - 10027458)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

1) Cardiorespiratory arrest
CORE UnLabeled
2) urinary tract infection
CORE Labeled
3) stroke cerebrovascular accident
CORE Labeled
4) lung metastases
CORE Labeled

2) Drug : Eligard® (Leuprolide acetate)
Active Substance : 1) Leuprolide acetate
Drug Characterization : Suspect
Form of Admin : 1) Injection
Lot Number : 1) Unknown
Daily Dose : (22.5 milligram(s), 1 in 3 Month)
Route of Admin : 1) Subcutaneous
Indications : 1) Prostate cancer [10060862 - Prostate cancer]
Therapy Dates : 1) From : 24/Jul/2023 To :Not applicable
Action(s) Taken With Drug : Not applicable

Causality

1) Cardiorespiratory arrest (Cardio-respiratory arrest - 10007617, Cardio-respiratory arrest - 10007617)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

2) urinary tract infection (Urinary tract infection - 10046571, Urinary tract infection - 10046571)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

3) stroke cerebrovascular accident (Cerebrovascular accident - 10008190, Cerebrovascular accident - 10008190)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

4) lung metastases (Lung metastases - 10025111, Metastases to lung - 10027458)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

1) Cardiorespiratory arrest
CORE UnLabeled
2) urinary tract infection
CORE Labeled
3) stroke cerebrovascular accident
CORE Labeled
4) lung metastases
CORE Labeled

3) Drug : Eligard® Unspecified Device (Leuprolide acetate)
Active Substance : 1) Leuprolide acetate
Drug Characterization : Suspect
Form of Admin : 1) Injection

Continuation Sheet for CIOMS report

Lot Number : 1) Unknown
Indications : 1) Prostate cancer [10060862 - Prostate cancer]
Action(s) Taken With Drug : Not applicable

Causality

1) Cardiorespiratory arrest (Cardio-respiratory arrest - 10007617, Cardio-respiratory arrest - 10007617)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

2) urinary tract infection (Urinary tract infection - 10046571, Urinary tract infection - 10046571)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

3) stroke cerebrovascular accident (Cerebrovascular accident - 10008190, Cerebrovascular accident - 10008190)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

4) lung metastases (Lung metastases - 10025111, Metastases to lung - 10027458)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

1) Cardiorespiratory arrest
CORE
2) urinary tract infection
CORE
3) stroke cerebrovascular accident
CORE
4) lung metastases
CORE

15. DAILY DOSE(S) (Continuation...)

Dosage Text :

Drug 1 :Eligard®

1) ELIGARD 45 MG x 1 LIO x 1 JER

Drug 2 :Eligard®

1) ELIGARD 22.5 MG x 1 LIO x 2 JER